Cancer Research Technology
Log in Register
Menu

Anti-Lewis Y [C14]

Info

Catalogue Number 153394
Applications ELISA FACS IHC
Antigen/Gene or Protein Targets Lewis Y
Reactivity Human
Relevance MAbs targeting both Lewis(y) and Lewis(b) may have a therapeutic advantage over mAbs targeting just one hapten. 692/29 has a more restricted normal tissue distribution and a higher antigen threshold for killing which should reduce its toxicity compared to a Lewis(y) specific mAb. 692/29 has an ability to directly kill tumours whereas the anti-Lewis(b) mAb does not. This suggests that Lewis(y) but not Lewis(b) are functional glycans. 692/29 showed good anti-tumour responses in vivo and is a strong therapeutic candidate.
Host Mouse
Immunogen Tumor cells
Subclass IgG
Strain Balb/c
Research Area Cancer, Epigenetics & Nuclear Signalling

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Durrant et al. 1989. J Natl Cancer Inst. 81(9):688-96. PMID: 2468779.

Flow cytometric screening of monoclonal antibodies for drug or toxin targeting to human cancer.

Europe PMC ID: 2468779


Add a reference

References: 2 entries

Durrant et al. 1989. J Natl Cancer Inst. 81(9):688-96. PMID: 2468779.

Flow cytometric screening of monoclonal antibodies for drug or toxin targeting to human cancer.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor